...Marya Lieberman and Joanne Cogdell who are recipients of a Trailblazer Award! |
Marya Liberman, professor in the Department of Chemistry and Biochemistry, and Joanne Cogdell, chief executive officer for Naxos Neighbors, received the Trailblazer Award which is aimed at supporting collaborative, community-engaged research projects focused on topics that have potential to improve health equity in Indiana. A summary of their proposal can be found below.
|
Implementing Community Drug Checking to Inform Personal and Community Harm Reduction Responses in a Regulation Restrictive Community
|
Project area and significance: The rise in opioid overdose deaths across Indiana highlights the importance of implementing proven harm reduction (HR) efforts and monitoring the drug supply at the community level to detect emerging hazards like benzodiazepines and xylazine. People who use drugs (PWUD) are willing to submit drug samples for drug checking and implement HR practices as a result. However many barriers exist, such as regulations that prevent people from bringing illicit drugs to clinics for drug checking. We are looking for an alternative model.
Geographic Area: St. Joseph County, Indiana, as a model of a regulation restrictive area
Target Population: 50 PWUD and people recently in recovery (PRIR)
Project aims and partnership: Naxos Neighbors will collaborate with HR and substance use treatment centers to train PWUD and PRIR to use fentanyl, benzodiazepine, and xylazine test strips at home. We will evaluate knowledge, attitudes, and practices related to the test strips to see if our training process is effective. Lieberman's lab has developed a procedure to detect drugs on used FTS. Participants will be asked to return their used FTS for mass spec analysis, with anonymous results from the test strips and the LCMS analysis shared with stakeholders.
Expected Outcomes: We will develop and test drug checking protocols aligned with the motivations and capacity of PWUD and PRIR and suitable for use in regulation restrictive communities. We will learn what drugs are actually circulating in St. Joseph County. These outcomes could help reduce mortality and morbidity from drug overdoses in areas where drug checking faces regulatory restrictions.
Proposed next steps/sustainability/dissemination: We would like to expand this program to cover the other 83 counties in Indiana that restrict drug checking at clinical sites. The CDC’s Overdose Data 2 Action program is a targeted funding source.
|
|
|
2023 Indiana CTSI Annual Meeting |
September 22, 2023
9:00 a.m. – 3:30 p.m. EDT
Hine Hall, 875 West North Street, Indianapolis, IN 46202
|
|
|
IUSCCC Heme Focused Investigator Initiated Trial (IIT) Pilot Funding |
Notice of Intent Submission Deadline: August 24. 2023
Full Submission Deadline: September 26, 2023
|
The IU Simon Comprehensive Cancer Center (IUSCCC) Hematopoiesis & Hematological Malignancies (HHM) and Experimental & Developmental Therapeutics (EDT) Programs are inviting proposals from members with a focus on hematopoiesis & hematological malignancies focused Investigator Initiated Trials (IITs).
The duration of this pilot funding is one year and the budget should not exceed $100,000.
Investigators wishing to apply to this funding mechanism must first submit a Notice of Intent for approval to Crystal Banks. Once approved, the link for submitting the online application will be sent.
Contact for Questions: Huda Salman or Mat Opyrchal
|
|
|
CTSI Postdoctoral Training Awards in Translational Research (T32)
|
Submission Deadline: October 26, 2023
|
The Indiana Clinical and Translational Sciences Institute (CTSI) T32 Postdoctoral Training Awards, funded in part by NCATS, are designed to provide promising postdoctoral fellows with the opportunity to be mentored in research-intensive multi-disciplinary settings toward the goal of developing careers across the spectrum of translational research.
Emphasis of CTSI postdoctoral training awards in translational research are to move findings from basic laboratory and pre-clinical research (referred to as T1 research) toward the development of new treatment options or interventions or clinical trials (referred to as T2 research) to eventual dissemination or clinical implementation (referred to as T3 research) to studying population health outcomes and health metrics (referred to as T4 research). The phases of translational research may not necessarily be linear and can jump steps depending on the research project and the starting point. The goal of the CTSI is to make awards at all of these stages.
Funding for all postdoctoral training awards is for up to two years (with the 2nd year of funding contingent upon review and demonstration of satisfactory progress). Benefits include salary support as well as health insurance and research training related expenses.
Applications will be accepted for two tracks:
|
-
Community-Public Health Track: Available for those postdoctoral fellows who have a keen interest for directed training in T3 to T4 translational research in the areas of clinical, health care delivery, public health, population health, or community or policy based efforts. It is important that the translational research have clear applications to human disease and health outcomes.
-
Traditional Track: Available for postdoctoral fellows who have an interest in undertaking a translational research project tailored to his or her interests while working in a research environment with mentors who can help the fellow develop the necessary skills to become a successful translational science researcher.
|
|
|
Neuroscience Institute (NSI) Collaborative Pilot Research Grant
|
Submission Deadline: October 31, 2023
|
The overarching goal of the Neurosciences Institute (NSI) Collaborative Pilot Grant is to provide pilot funding to support new research collaborations that will produce preliminary data needed to prepare subsequent research grant applications. Applications may include basic, translational, or clinical neuroscience researchers. Project must be responsive to the scientific mission of the NSI.
This initiative will provide $25,000, per year for a period of up to two years (total funding $50,000); second year of funding will be contingent on progress (as evaluated by the Pilot Grant Committee).
Contact for Questions: Lindsay Treadway
|
|
|
Must be led by an IUSCCC member
|
IUSCCC Community-Academic Collaborative Program Award |
Letter OF Intent Submission Deadline: Rolling submission
Full Submission Deadline: Rolling submission
|
IU Simon Comprehensive Cancer Center, Office of Community Outreach and Engagement is inviting collaborative proposals for implementing evidence-based cancer related programs within the community. Proposals should focus on the cancer burden in Indiana. The program should have an evaluation component and priority will be given to one of the major cancer burdens in Indiana including lung, breast, colon, pancreas, prostate and cervical. We are particularly interested in programs that can lower risk behaviors related to cancers which drive cancer incidence and morbidity. Of particular interest are community-led programs that will increase our reach or understanding of the underserved populations in Indiana. The project must be co-led by an IUSCCC faculty member and community advocate or partner.
The duration of this funding is one year, and the budget should not exceed $15,000.
Investigators wishing to apply to this funding mechanism must first submit a Letter of Intent for approval to Crystal Baker. Once approved, the link for submitting the online application will be sent.
Contact for Questions: Crystal Baker
|
|
|
IUSCCC “Near-Miss” NIH R01 Initiative |
The IU Simon Comprehensive Cancer Center (IUSCCC) is providing an opportunity to fund cancer focused PI-directed applications to the National Institutes of Health that have been reviewed once and missed the NIH pay line and have a high potential for obtaining external funding. The goal is to increase the cancer focused NIH funding base in the IUSCCC. Non-NCI targeted applications should have significant cancer relevance. This opportunity is limited to those who are IUSCCC members.
Investigators wishing to apply to this funding mechanism must first submit a draft cover letter (letter of intent) for approval by the IUSCCC Executive Committee before working with a Coordinator to submit a full application. Once approved, the link for submitting the online application will be sent.
Maximum allowable amount for R01, R42 and R44 grants is $50K with P01 and SPORE funding amounts evaluated on a case-by-case basis.
Contact for Letter of Intent and Questions: Kaitlin Condron or Crystal Baker
|
|
|
If you have any questions about Indiana CTSI grants, programs, or upcoming events please feel free to reach out to co-navigators Jessica Brookshire or Paul Helquist.
|
|
|
The Indiana CTSI includes Indiana University, Purdue University, and the University of Notre Dame as the major academic partners along with a number of other institutions and entities in the state.
It is funded by a Clinical and Translational Sciences Award from the National Institutes of Health amounting to some $38 million for the current seven-year funding period of 2023-2030. This funding is supplemented by additional support from many other institutional and corporate partners.
Funding is provided to researchers by many mechanisms to promote translational and collaborative research among the partner institutions.
For more information, please visit: indianactsi.org
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
317 Main Building | Notre Dame, IN 46556 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|